Pharvaris NV美股招股说明书(2026-05-08版)

3,874,664 ordinary shares We are offering 3,874,664 of our ordinary shares, nominal value €0.12 per ordinary share (“ordinary shares”). Our ordinary shares are listed on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “PHVS.” On May7, 2026, the last sale price ofour ordinary shares as reported on Nasdaq was $29.68 per ordinary share. We are a “foreign private issuer” as defined under the Securities and Exchange Commission (“SEC”) rules and, as such, we have elected tocomply with certain reduced public company reporting requirements for this prospectus supplement and future filings. Please see “Pharvaris N.V.—Summary—Implications of Being a Foreign Private Issuer” below. Investing in our ordinary shares involves a high degree of risk. You should review carefully the risks anduncertainties described under the header “Risk Factors” contained in this prospectus supplement beginning on pageS-8 and under similar headings in the other documents that are incorporated by reference into this prospectussupplement and the accompanying prospectus. You should read the entire prospectus supplement and the accompanying prospectus, including any information incorporated byreference herein or therein, carefully before you make your investment decision. PerOrdinaryShareTotalOffering price$29.68000$115,000,028Underwriting discounts and commissions(1)$1.78080$6,900,002Proceeds, before expenses, to us$27.89920$108,100,026 (1)We refer you to “Underwriting” beginning on page S-28 for additional information regarding underwriting compensation. We have granted the underwriters an option for a period of 30 days to purchase up to an additional581,199 ordinary shares from us, at the publicoffering price, less the underwriting discounts and commissions. Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy oraccuracy of this prospectus. Any representation to the contrary is a criminal offense. The ordinary shares will be ready for delivery on or about May 11, 2026. Joint Book-Running Managers WellsFargoSecurities MorganStanley Table of Contents TABLE OF CONTENTSPROSPECTUS SUPPLEMENT PRESENTATION OF FINANCIAL INFORMATIONS-1TRADEMARKSS-1ABOUT THIS PROSPECTUS SUPPLEMENTS-1SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSS-2PROSPECTUS SUPPLEMENT SUMMARYS-5THE OFFERINGS-7RISK FACTORSS-8USE OF PROCEEDSS-10DIVIDEND POLICYS-11DILUTIONS-12MATERIAL UNITED STATES FEDERAL INCOME TAX AND DUTCH TAX CONSIDERATIONS OF ORDINARY SHARESS-13UNDERWRITINGS-24LEGAL MATTERSS-33EXPERTSS-34WHERE YOU CAN FIND MORE INFORMATIONS-35INCORPORATION BY REFERENCES-36 PROSPECTUS ABOUT THIS PROSPECTUSWHERE YOU CAN FIND MORE INFORMATIONSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSPHARVARIS N.V.RISK FACTORSUSE OF PROCEEDSDESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATIONCOMPARISON OF DUTCH LAW AND OUR ARTICLES OF ASSOCIATION AND U.S. CORPORATE LAWDESCRIPTION OF DEBT SECURITIESDESCRIPTION OF WARRANTSDESCRIPTION OF PURCHASE CONTRACTSDESCRIPTION OF UNITSFORMS OF SECURITIESPLAN OF DISTRIBUTIONINCORPORATION OF CERTAIN INFORMATION BY REFERENCEENFORCEMENT OF JUDGMENTSEXPENSESLEGAL MATTERSEXPERTS Table of Contents PRESENTATION OF FINANCIAL INFORMATION We report under IFRS Accounting Standards as issued by the International Accounting Standards Board. None of the financial statementsincorporated by reference herein were prepared in accordance with generally accepted accounting principles in the United States. We present ourconsolidated financial statements in euros. We have made rounding adjustments to some of the figures included in this prospectus supplement.Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them. Unless otherwise indicated, all references in this prospectus supplement to “€,” “euro,” “EUR” or “cents” are to the currency introduced atthe start of the third stage of the European Economic and Monetary Union pursuant to the Treaty on the Functioning of the European Union, asamended. All references to “$,” “US$” or “U.S. dollars” are to the lawful currency of the United States. Solely for the convenience of the reader, certain euro amounts herein have been translated into U.S. dollars at the rate of €1.00 to $1.1750, theaverage exchange rate quoted as of December31, 2025 by the European Central Bank. These translations should not be considered representationsthat any such amounts have been, could have been or could be converted into U.S. dollars at that or any other exchange rate as at that or any otherdate. TRADEMARKS All trademarks, trade names and service marks appearing in this prospectus supplement are the property of their respective owners. Solely forconvenience, the trademarks and trade names in this prospectus supplement are referred to without the symbols®and™, but such references shouldnot be construed as any indication that their respective owners will not assert